Idorsia

Focus: Idorsia is a Swiss biotech specializing in small-molecule therapeutics for cardiovascular and psychiatric indications. The company is heavily dependent on QUVIVIQ (daridorexant), its peak-stage insomnia drug, which currently represents 100% of revenue.

Cardiovascular Psychiatry

Profile data last refreshed 6h ago · AI intelligence enriched 2w ago

Open Jobs

About Idorsia

AI assessmentNot Hiring

No open roles listed right now. Follow Idorsia to get notified when they start hiring — the background below is worth knowing for when they do.

Generated by Claude from Idorsia's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

QUVIVIQ

Insomnia; Orexin Receptor Antagonist

$16M Part D

Peak

Help build intelligence for Idorsia

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

Natural History Study for Pediatric Patients With Early Onset of Either GM1 Gangliosidosis, GM2 Gang

GM1 Gangliosidosis

N/A

Clinical Trials (1)

NCT04470713Natural History Study for Pediatric Patients With Early Onset of Either GM1 Gangliosidosis, GM2 Gangliosidoses, or Gaucher Disease Type 2

N/A

Sleep and diet

Sleep

N/A

Clinical Trials (1)

NCT07212101Sleep in Collegiate Baseball Players

N/A

Daridorexant

Insomnia

N/A

A Prospective Registry Study of Patients With Hypertension

Hypertension (HTN)

N/A

Clinical Trials (1)

NCT07579260IMPACT-HTN Study of Patients With Hypertension

N/A

Daridorexant

Insomnia Disorder

N/A

Clinical Trials (4)

NCT07555743Efficacy and Safety of Daridorexant in Patients With Major Depressive Disorder and Insomnia

Phase 4

NCT07843329A Trial to See if Daridorexant Can Help Adults and Elderly People With Insomnia Sleep Better During the Night and Function Better During the Day

Daridorexant 50 mg

Insomnia

N/A

Clinical Trials (1)

NCT06311864Real-World Observational Study on Patient-Reported Outcomes in the Treatment of Insomnia With Daridorexant in Canada

N/A

ACT-541468 25 mg

Hepatic Impairment

Phase 1

Clinical Trials (1)

NCT03713242A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment

Phase 1

ACT-541468

Renal Insufficiency

Phase 1

Clinical Trials (1)

NCT04024332Study of the Way the Body Takes up, Distributes, and Gets Rid of ACT-541468 in Subjects With Abnormal Kidney Function Compared to Healthy Subjects

Phase 1

AC-082

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT02702648First-in-man Study of Single and Multiple Ascending Doses of a New Drug for Neurological Disorders

Phase 1

Lucerastat

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT02944487A Study to Assess the Safety and Pharmacokinetics of Lucerastat (OGT 923) in Healthy Subjects

Phase 1

Lucerastat

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT03380455Effect of Cimetidine on the Pharmacokinetics of Lucerastat in Healthy Subjects

Phase 1

Daridorexant 25 mg

Healthy

Phase 1

Clinical Trials (1)

NCT05702177A Study of the Effect of Daridorexant on Nighttime Body Posture, the Noise Level Required to Wake up, and the Ability to Remember Words Previously Presented

Phase 1

ACT-1004-1239

Healthy

Phase 1

Clinical Trials (1)

NCT03869320A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ACT-1004-1239 in Healthy Male Subjects

Phase 1

Lucerastat

Fabry Disease

Phase 1

Clinical Trials (1)

NCT02930655A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease

Phase 1

ACT-541468

Healthy

Phase 1

Clinical Trials (1)

NCT03892902A Clinical Study to Assess Next-day Driving Performance Following Administration of ACT-541468 in Middle-aged and Elderly Subjects

Phase 1

ACT-541468

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT03101189A Study of ACT-541468 in Healthy Japanese and Caucasian Subjects

Phase 1

ACT-462206 5 mg

Safety

Phase 1

Clinical Trials (1)

NCT01954589Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-462206

Phase 1

ACT-541468

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT02571855A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of ACT-541468 in Healthy Young Adults and Elderly Subjects

Phase 1

Daridorexant

Healthy

Phase 1

Clinical Trials (1)

NCT05632393A Study to Measure Daridorexant in Breast Milk of Healthy Lactating Women

Phase 1

Clazosentan

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT03657446A Study in Healthy Subjects to Investigate Whether Administration of Clazosentan Can Affect Normal Heart Function

Phase 1

Midazolam

Healthy

Phase 1

Clinical Trials (1)

NCT03363984Pharmacokinetic Interaction Between Midazolam and ID-082 in Healthy Subjects

Phase 1

ACT-132577

Severe Renal Impairment

Phase 1

Clinical Trials (1)

NCT03165071A Study to Evaluate ACT-132577 in Healthy Subjects and in People With Severe Kidney Disease

Phase 1

ACT-541468

Healthy

Phase 1

Clinical Trials (1)

NCT03609775A Study to Investigate the Drug-drug Interactions Between ACT-541468 and Ethanol in Healthy Subjects

Phase 1

Aprocitentan

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT03245229A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-132577 Can Affect Rosuvastatin's Fate in the Body (Amount and Time of Presence in the Blood)

Phase 1

ACT-129968 500 mg tablet

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT01877629Clinical Study to Assess the Pharmacokinetics, Safety, and Tolerability of ACT-129968 in Healthy Subjects

Phase 1

Aprocitentan

Hepatic Impairment

Phase 1

Clinical Trials (1)

NCT04252495The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics

Phase 1

ACT-1004-1239

Healthy

Phase 1

Clinical Trials (1)

NCT05549531A Study to Investigate the Effect of Itraconazole on the Way the Body Absorbs, Distributes, and Gets Rid of ACT-1004-1239 Given as a Single Dose of 10 mg to Healthy Male Subjects

Phase 1

5 mg ACT-281959 prodrug formulation I

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

Phase 1

Clinical Trials (1)

NCT01954615Single-ascending Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-281959 / ACT-246475 in Healthy Male Subjects

Phase 1

ACT-539313

Healthy

Phase 1

Clinical Trials (1)

NCT05254548A Study to Investigate the Effect of Single and Repeated Oral Doses of ACT-539313 on What the Body Does to Flurbiprofen, Omeprazole, Midazolam in Healthy Subjects

Phase 1

Daridorexant

Healthy

Phase 1

Clinical Trials (1)

NCT04390334A Study in Healthy Male Subjects to Investigate the Effect of Famotidine and Efavirenz on the Way the Body Takes up, Distributes, and Gets Rid of Daridorexant.

Phase 1

Daridorexant

Healthy

Phase 1

Clinical Trials (1)

NCT04250506A Study to Assess the Effect of Single Doses of Daridorexant on Electrocardiogram Parameters in Healthy Subjects

Phase 1

Midazolam

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT03017495A Clinical Study to Investigate the Potential Interactions Between Food and ACT-541468 and Between ACT-541468 and Midazolam

Phase 1

Clazosentan

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT03596294A Study in Healthy Male Subjects to Investigate Whether Administration of Rifampicin Can Affect the Fate of Clazosentan in the Body of Clazosentan

Phase 1

Ethinyl Estradiol / Levonorgestrel Oral Tablet

Drug Drug Interaction

Phase 1

Clinical Trials (1)

NCT06799884A Drug-drug Interaction Trial in Healthy Female Participants to Investigate the Effect of Aprocitentan on Combined Hormonal Contraceptives

Phase 1

14C-radiolabeled ACT-132577

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT03100591A Study to Evaluate ACT-132577 in Healthy Male Subjects

Phase 1

Aprocitentan 25mg

Healthy Subjects

Phase 1

ACT-451840 10 mg

Healthy

Phase 1

Clinical Trials (1)

NCT02186002Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-451840 in Healthy Subjects (Part A)

Phase 1

ACT-541468

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT02526888Pharmacokinetic Interaction Between Diltiazem and ACT-541468 in Healthy Subjects

Phase 1

ACT-777991

Healthy

Phase 1

Clinical Trials (2)

NCT07667569A Study to Learn How Safe ACT-777991 is and How Well it Works in Adults With Non-segmental Vitiligo

Phase 2

NCT04798209A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-777991 in Healthy Subjects

ACT-453859 1 mg

Healthy

Phase 1

Clinical Trials (1)

NCT02381496A Study to Assess the Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Ascending Single Doses (Including Food Interaction) and Ascending Multiple Doses of ACT-453859, and Multiple Doses of Setipiprant (ACT-129968)

Phase 1

ACT-709478

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT03165097Study to Evaluate Safety and Tolerability of ACT-709478 in Healthy Subjects

Phase 1

ACT-1014-6470

Healthy

Phase 1

Clinical Trials (1)

NCT04608513A Placebo-controlled Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects

Phase 1

Treatment period A

Drug Drug Interaction

Phase 1

Clinical Trials (1)

NCT05123820Pharmacokinetics of Omeprazole and Midazolam When Co-administered With ACT-1014-6470

Phase 1

ACT-541468

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT02919319A Single Ascending Dose Study of ACT-541468 in Healthy Male Subjects